Ligand Reports First Quarter 2024 Financial Results May 7, 2024 04:00PM
Ligand Reports Third Quarter 2023 Financial Results Nov 8, 2023 04:01PM
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Sep 22, 2023 09:00AM
Ligand Reports Second Quarter 2023 Financial Results Aug 8, 2023 04:01PM
Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) Present Positive Pivotal Phase 2b Trial Data Jun 5, 2023 05:53AM
View Older Stories

Jun 2, 2023 06:41PM Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Jan 19, 2023 07:46AM Jazz Pharmaceuticals (JAZZ), Zymeworks (ZYME) Announce 84% OS at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Jan 19, 2023 07:45AM Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Dec 21, 2022 07:30AM Jazz (JAZZ) and Zymeworks (ZYME) Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Dec 21, 2022 07:30AM Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Nov 14, 2022 09:00AM STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING
Nov 3, 2022 10:43AM Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
Nov 1, 2022 04:15PM Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
Oct 26, 2022 04:15PM Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
Oct 19, 2022 06:07AM Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
Oct 19, 2022 06:01AM Jazz (JAZZ) and Zymeworks (ZYME) Enter License Agreement to Develop and Commercialize Zanidatamab
Oct 19, 2022 06:00AM Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Sep 15, 2022 04:30PM Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
Aug 31, 2022 04:15PM Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
Aug 18, 2022 07:30AM Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
Aug 3, 2022 04:05PM Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
Jul 20, 2022 04:15PM Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
Jun 28, 2022 07:33AM Jazz Pharmaceuticals (JAZZ) Phase 3 Trial Evaluating Nabiximols Oromucosal Spray Did Not Meet Primary Endpoint
Jun 28, 2022 07:30AM Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Jun 7, 2022 07:31AM Jazz Pharmaceuticals (JAZZ) Reports Positive Data from Phase 2/3 Trial of Rylaze in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Jun 7, 2022 07:30AM Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASC
Jun 1, 2022 04:15PM Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference
Jun 1, 2022 07:45AM Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
May 12, 2022 11:57AM Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
May 9, 2022 07:00AM Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
May 4, 2022 04:10PM Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance
May 4, 2022 04:06PM Jazz Pharmaceuticals (JAZZ) and Sumitomo Enter Exclusive License Agreement to Develop and Commercialize DSP-0187
May 4, 2022 04:05PM Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
May 3, 2022 04:15PM Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference
Apr 20, 2022 04:15PM Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
Apr 8, 2022 01:00PM Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types
Apr 7, 2022 07:01AM Jazz Pharmaceuticals (JAZZ) and Werewolf (HOWL) Enter Exclusive Global License and Collaboration Agreement to Develop WTX-613
Apr 7, 2022 07:00AM Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
Mar 29, 2022 04:15PM Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences
Mar 28, 2022 06:00AM Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
Mar 25, 2022 05:47AM Jazz Pharmaceuticals (JAZZ) Announces Over $100M Investment in UK Manufacturing
Mar 25, 2022 03:00AM Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
Mar 24, 2022 07:32AM Jazz Pharmaceuticals (JAZZ) Enrolls First Patient in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca Monotherapy
Mar 24, 2022 07:30AM Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors
Mar 8, 2022 04:35PM Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 1, 2022 04:05PM JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS
Feb 28, 2022 04:15PM Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
Feb 15, 2022 04:15PM Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022
Feb 2, 2022 07:34AM Jazz Pharmaceuticals (JAZZ) Completes U.S. FDA sBLA for Rylaze Monday/Wednesday/Friday Dosing Schedule
Feb 2, 2022 07:30AM Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule
Jan 10, 2022 07:31AM Jazz Pharmaceuticals (JAZZ) Issues Long-Term Vision and Guidance
Jan 10, 2022 07:30AM Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader
Jan 5, 2022 07:46AM Jazz Pharmaceuticals (JAZZ) Announces Publication of Positive Phase 3 Data of Xywav Oral Solution for Idiopathic Hypersomnia
Jan 5, 2022 07:45AM Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
Jan 3, 2022 04:15PM Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
View Older Stories